Histopathological features of endometrial carcinomas associated with POLE mutations: Implications for decisions about adjuvant therapy

Histopathology

Volumn 68, Issue 6, 2016, Pages 916-924

  Bakhsh, Salwa ^a   Kinloch, Mary ^a   Hoang, Lien N ^a   Soslow, Robert A ^b   Köbel, Martin ^c   Lee, Cheng Han ^d   McAlpine, Jessica N ^e   McConechy, Melissa K ^a   Gilks, C Blake ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c CALGARY LABORATORY SERVICES   (Canada)

^d UNIVERSITY OF ALBERTA   (Canada)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Endometrial carcinoma; Mutations; POLE; TCGA

Indexed keywords

ANTINEOPLASTIC AGENT; DNA DIRECTED DNA POLYMERASE EPSILON; MISMATCH REPAIR PROTEIN; PROTEIN MSH2; PROTEIN MSH6; PROTEIN P53; DNA DIRECTED DNA POLYMERASE ALPHA; POLE PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER STAGING; CLEAR CELL CARCINOMA; CLEAR CELL ENDOMETRIAL CARCINOMA; CLINICAL DECISION MAKING; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CARCINOMA; FEMALE; GENE MUTATION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPH VESSEL METASTASIS; LYMPHOCYTE; MITOSIS; MITOSIS INDEX; MIXED ENDOMETRIAL TUMOR; MIXED TUMOR; MULTIMODALITY CANCER THERAPY; PERITUMORAL LYMPHOCYTE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; TUMOR ASSOCIATED LEUKOCYTE; ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; ADJUVANT RADIOTHERAPY; CYSTADENOCARCINOMA; ENDOMETRIUM TUMOR; GENETICS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MUTATION; PATHOLOGY; RISK FACTOR; TISSUE MICROARRAY; VERY ELDERLY;

ADENOCARCINOMA, CLEAR CELL; ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CARCINOMA, ENDOMETRIOID; CHEMOTHERAPY, ADJUVANT; CYSTADENOCARCINOMA, SEROUS; DNA POLYMERASE II; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MUTATION; NEOPLASM GRADING; RADIOTHERAPY, ADJUVANT; RISK FACTORS; TISSUE ARRAY ANALYSIS;

EID: 84951310691     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12878     Document Type: Article

References (24)

1. Howlader N, Noone A, Krapcho M. SEER cancer statistics review, 1975-2011. Bethesda, MD: National Cancer Institute. Available at: http://Seer.cancer.gov/csr/1975_2011/.
2. Bansal N, Yendluri V, Wenham RM. The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies. Cancer Control 2009; 16; 8-13.
3. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol. Oncol. 1983; 15; 10-17.
4. McConechy MK, Ding J, Cheang MC et al. Use of mutation profiles to refine the classification of endometrial carcinomas. J. Pathol. 2012; 228; 20-30.
5. Hoang LN, McConechy MK, Kobel M et al. Histotype-genotype correlation in 36 high-grade endometrial carcinomas. Am. J. Surg. Pathol. 2013; 37; 1421-1432.
6. Han G, Sidhu D, Duggan MA et al. Reproducibility of histological cell type in high-grade endometrial carcinoma. Mod. Pathol. 2013; 26; 1594-1604.
7. Soslow RA. Endometrial carcinomas with ambiguous features. Semin. Diagn. Pathol. 2010; 27; 261-273.
8. Cancer Genome Atlas Research Network; Kandoth C, Schultz N et al. Integrated genomic characterization of endometrial carcinoma. Nature 2013; 497; 67-73.
9. Church DN, Briggs SE, Palles C et al. DNA polymerase epsilon and delta exonuclease domain mutations in endometrial cancer. Hum. Mol. Genet. 2013; 22; 2820-2828.
10. Stelloo E, Bosse T, Nout RA et al. Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative. Mod. Pathol. 2015; 28; 836-844.
11. Church DN, Stelloo E, Nout RA et al. Prognostic significance of POLE proofreading mutations in endometrial cancer. J. Natl Cancer Inst. 2014; 107; 402.
12. Meng B, Hoang LN, McIntyre JB et al. POLE exonuclease domain mutation predicts long progression-free survival in grade 3 endometrioid carcinoma of the endometrium. Gynecol. Oncol. 2014; 134; 15-19.
13. Hussein YR, Weigelt B, Levine DA et al. Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations. Mod. Pathol. 2015; 28; 505-514.
14. BC Cancer Agency. Available at: http://Www.bccancer.bc.ca/HPI/CancerManagementGuidelines/gynecology/endometrium/mngmt.htm (updated 2012).
15. Talhouk A, McConechy M, Leung S et al. A clinically applicable molecular-based classification for endometrial cancers. Br. J. Cancer 2015; 113; 299-310.
16. Shia J, Black D, Hummer AJ, Boyd J, Soslow RA. Routinely assessed morphological features correlate with microsatellite instability status in endometrial cancer. Hum. Pathol. 2008; 39; 116-125.
17. Kurman R, Carcangiu M, Herrington S, Young R eds. World Health Organization classification of tumors of female reproductive organs. 4th ed. Lyon: IARC Press, 2014; 121-133.
18. McConechy MK, Talhouk A, Li-Chang HH et al. Detection of DNA mismatch repair (MMR) deficiencies by immunohistochemistry can effectively diagnose the microsatellite instability (MSI) phenotype in endometrial carcinomas. Gynecol. Oncol. 2015; 137; 306-310.
19. Kobel M, Reuss A, Bois A et al. The biological and clinical value of p53 expression in pelvic high-grade serous carcinomas. J. Pathol. 2010; 222; 191-198.
20. Alkushi A, Abdul-Rahman ZH, Lim P et al. Description of a novel system for grading of endometrial carcinoma and comparison with existing grading systems. Am. J. Surg. Pathol. 2005; 29; 295-304.
21. Kobel M, Bak J, Bertelsen BI et al. Ovarian carcinoma histotype determination is highly reproducible, and is improved through the use of immunohistochemistry. Histopathology 2014; 64; 1004-1013.
22. van Gool IC, Eggink FA, Freeman-Mills L et al. POLE Proofreading mutations elicit an antitumor immune response in endometrial cancer. Clin. Cancer Res. 2015; 21; 3347-3355.
23. Le DT, Uram JN, Wang H et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 2015; 372; 2509-2520.
24. Billingsley CC, Cohn DE, Mutch DG, Stephens JA, Suarez AA, Goodfellow PJ. Polymerase varepsilon (POLE) mutations in endometrial cancer: clinical outcomes and implications for Lynch syndrome testing. Cancer 2015; 121; 386-394.